Quality Control
Proteomics International is experienced in delivering quality, accurate results that help progress your research and business.
- Proteomics International is accredited for compliance with ISO/IEC 17025 Chemical Testing and has held this accreditation since 2009.
- Proteomics International also holds Research and Development accreditation to ISO/IEC 17025. Proteomics International has held this accreditation since 2016. For further detail of Proteomics International’s scope of accreditation, please refer to the NATA website, using accreditation number 16838.
- Proteomics International is accredited for compliance with ISO/IEC 13485, the most widely-used international standard for quality management systems in the manufacture of medical devices, and has held this accreditation since 2021.
- Proteomics International has over 20 years of experience in analysing proteins and in the method development of quantitative assays.
Accreditation recognises Proteomics Internationals’ ability to consistently achieve technically valid, traceable and reproducible results. In Australia, accreditation is assessed by NATA (the National Association of Testing Authorities). ISO/IEC 17025 is recognised worldwide as the main ISO standard used by testing and calibration laboratories, and is the most widely used laboratory standard for US Federal testing laboratories. ISO/IEC 17025 is used by the FDA’s testing facilities. In 2009, the company’s laboratory was the first facility in the world to receive ISO 17025 accreditation for proteomics services.
The quality of Proteomics International’s technical expertise is demonstrated by its discovery of the protein biomarkers associated with Diabetic Kidney Disease. This discovery is currently being commercialised as a diagnostic and prognostic test for Diabetic Kidney Disease – PromarkerD. Proteomics International’s discovery, and the rigour behind the research phase was sufficiently notable that the world’s leading mass spectrometer manufacturer, AB Sciex , released a Technote using Proteomics International’s research pipeline for Diabetic Kidney Disease to illustrate Biomarker Discovery.
